RiaSTAP

Drug Overview

In the highly specialized field of hematology, managing acute bleeding requires rapid, precise interventions. RiaSTAP is a critical medication belonging to the Fibrinogen Concentrate (Human) drug class. As a human plasma-derived BIOLOGIC, it plays a vital role in providing immediate blood-clotting support for patients missing a key protein required to stop bleeding.

For patients born with an inability to produce sufficient fibrinogen, this medication acts as a specialized TARGETED THERAPY. It directly replaces the exact missing protein, eliminating the need for massive transfusions of whole blood or plasma, which can strain the heart and carry higher risks.

• Generic Name: fibrinogen concentrate (human)
• US Brand Names: RiaSTAP
• Route of Administration: Intravenous (IV) infusion
• FDA Approval Status: FDA-approved for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia (complete lack of fibrinogen) and hypofibrinogenemia (dangerously low levels of fibrinogen).
  
  Explore essential facts about RiaSTAP. Discover its key medical uses, vital health benefits, potential side effects, and correct patient dosage.

What Is It and How Does It Work? (Mechanism of Action)

To understand how RiaSTAP works, it is helpful to look at how the body naturally stops bleeding. When a blood vessel is injured, the body triggers a chain reaction called the coagulation cascade. This process involves a series of proteins (clotting factors) that activate one another.

Fibrinogen, also known as Factor I, is the final and most important protein in this cascade. During a bleeding event, an enzyme called thrombin cuts the floating fibrinogen molecules into sticky threads called fibrin. These fibrin threads weave together to form a strong, net-like mesh. This mesh traps red blood cells and platelets, turning a fragile platelet plug into a solid, stable blood clot.

In patients with congenital fibrinogen deficiency, the body cannot form this final mesh, leading to uncontrolled bleeding. RiaSTAP provides a concentrated dose of human fibrinogen directly into the bloodstream. At the hematological level, it immediately supplies the raw material needed for the coagulation cascade to finish its job. By bypassing the need for vitamin K-dependent factors to build the clot alone, this BIOLOGIC allows the body to instantly create a fibrin net, achieving rapid and profound hemorrhage risk reduction.

FDA-Approved Clinical Indications

Primary Indication

Within the hematology category, the primary indication for RiaSTAP is the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency. Congenital means the condition is present from birth. This includes afibrinogenemia (where the patient makes no fibrinogen) and hypofibrinogenemia (where the patient makes very little). By raising the blood levels of fibrinogen, RiaSTAP allows these patients to successfully form blood clots during trauma, surgery, or spontaneous bleeding events.

Other Approved & Off-Label Uses

While officially approved for congenital (inherited) deficiencies, hematologists frequently explore its use in other critical bleeding scenarios:

• Acquired hypofibrinogenemia (Off-label): Used during massive hemorrhage, such as severe trauma or major cardiovascular surgery, where the body rapidly uses up its existing fibrinogen.
• Postpartum hemorrhage (Off-label): Used in severe bleeding after childbirth when natural fibrinogen levels plummet.
• Dysfibrinogenemia (Off-label): Used when a patient’s body makes fibrinogen, but the protein is abnormally shaped and does not work correctly.

Dosage and Administration Protocols

Dosing for RiaSTAP is highly individualized. It is strictly based on the patient’s body weight and their current baseline fibrinogen level. The clinical goal is typically to raise the patient’s fibrinogen blood level to at least 100 mg/dL to ensure adequate clotting.

Important Adjustments:

• Maximum Infusion Rates: The medication must be infused slowly. The maximum recommended infusion rate is 5 mL per minute for adults. For pediatric patients, the rate should be calculated to not exceed a comfortable volume based on their size.
• Renal/Hepatic Insufficiency: While there are no specific dose reductions required for kidney or liver impairment, liver disease can independently alter how the body clears clotting factors, requiring closer monitoring.
• Target Level Monitoring: Follow-up blood tests are required to ensure the target fibrinogen level (usually 100 mg/dL) has been reached and is maintained until the bleeding stops.

Clinical Efficacy and Research Results

Current clinical study data (2020-2026) strongly supports the efficacy of fibrinogen concentrate. In clinical trials evaluating congenital fibrinogen deficiency, RiaSTAP demonstrated a 100 percent efficacy rate in increasing fibrinogen levels to the target range. In real-world data tracking acute bleeding episodes, successful hemostasis (stopping of bleeding) is achieved in over 90 percent of treated episodes.

Furthermore, recent research emphasizes that using a targeted BIOLOGIC like RiaSTAP is far more effective and safer than older methods, such as using cryoprecipitate or fresh frozen plasma (FFP). RiaSTAP provides a standardized, highly concentrated dose without overloading the patient’s circulatory system with excess fluid, a critical advantage for pediatric patients and those with heart conditions.

Safety Profile and Side Effects

Black Box Warning

RiaSTAP does not have a standard “Black Box Warning.” However, it carries significant prescribing warnings regarding the risk of severe thrombosis (blood clots) and hypersensitivity reactions.

Common side effects (>10%)

Because this medication is a naturally occurring human protein, common side effects are generally mild. They may include:

• Fever
• Headache
• Chills
• Nausea or vomiting

Serious adverse events

• VTE/Thrombosis risk: The most significant danger. Because RiaSTAP promotes clotting, it can cause inappropriate and life-threatening blood clots, including deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction (heart attack).
• Hypersensitivity: Severe allergic reactions (anaphylaxis), including hives, wheezing, and dangerous drops in blood pressure.
• Pathogen Transmission: Because it is derived from human plasma, there is a theoretical risk of transmitting infectious agents, though rigorous viral inactivation steps make this extremely rare.

Management Strategies

If a patient develops signs of a severe allergic reaction, the infusion must be stopped immediately, and emergency medications (like epinephrine and antihistamines) should be administered. To manage the risk of thrombosis, doctors must carefully monitor the patient’s fibrinogen levels to ensure they do not accidentally overdose the patient, pushing the blood into a hyper-clottable state.

Research Areas

In the 2025-2026 research landscape, the focus on fibrinogen has expanded significantly into the emergency medicine and trauma sectors. Active clinical trials are investigating the routine use of RiaSTAP as a frontline TARGETED THERAPY for severe trauma patients before they even reach the hospital, aiming to stop massive hemorrhage faster. Additionally, researchers are exploring the development of recombinant (lab-grown) fibrinogen concentrates, which would completely eliminate the reliance on human plasma donors and remove any lingering risks of pathogen transmission.

Disclaimer: The research mentioned regarding the use of marstacimab in patients with inhibitors and in pediatric populations under 12 is an active area of investigation in 2026. While the “rebalancing” concept is theoretically ideal for inhibitor patients, specific FDA approval for these groups is distinct from the current approval for non-inhibitor patients.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Fibrinogen Activity Test: To determine the baseline level of fibrinogen in the blood.
• Coagulation Panel (PT/INR and aPTT): To assess overall blood clotting function.
• Complete Blood Count (CBC): To monitor red blood cell and platelet levels.

Precautions during treatment

• Thromboembolism Monitoring: Patients must be closely observed for signs of inappropriate clotting (e.g., chest pain, shortness of breath, unexplained leg swelling).
• Volume Overload Vigilance: While less of a risk than with plasma, heart rate and blood pressure should be monitored during the infusion.
• Transfusion Triggers: RiaSTAP stops bleeding but does not replace lost red blood cells. Patients who have lost massive amounts of blood may still require red blood cell transfusions to treat severe anemia.

“Do’s and Don’ts” List

• DO warm the vial to room temperature before mixing it with sterile water.
• DO gently swirl the vial to dissolve the powder; rigorous shaking will damage the fragile BIOLOGIC proteins.
• DO administer the medication within 8 hours of mixing it.
• DON’T mix RiaSTAP with any other medications or IV fluids in the same line.
• DON’T use this medication if you have a known history of severe allergic reactions to human blood products.
• DON’T ignore sudden chest pain, slurred speech, or leg pain after receiving this medication, as these are medical emergencies.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. The management of bleeding disorders requires specialized care. Always consult your hematologist or emergency care physician regarding your specific diagnosis, treatment options, and the risks associated with plasma-derived therapies.